Generic Name and Formulations:
Cladribine 1mg/mL; soln for IV infusion after dilution; preservative-free.
Various generic manufacturers
Indications for Cladribine:
Active hairy cell leukemia.
Give by continuous IV infusion for 7 consecutive days. 0.09mg/kg per day.
See full labeling.
Delay or discontinue if neurotoxicity or renal toxicity occurs. Myelosuppression. Active infection. Renal or hepatic insufficiency. Monitor blood counts (esp. during first 4–8 weeks post-dose), renal and hepatic function. Pregnancy (Cat.D), nursing mothers: not recommended.
Live attenuated vaccines: not recommended. Increased toxicity with myelosuppressive, immunosuppressive, or nephrotoxic agents.
Chlorinated purine nucleoside analog.
Severe myelosuppression (eg, neutropenia, anemia, thrombocytopenia), fever, infection, fatigue, nausea, rash, headache, inj site reactions, others; neurotoxicity, nephrotoxicity, tumor lysis syndrome (rare).